Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers

Misaka, Shingen; Abe, Osamu; Sato, Hideyuki; Ono, Tomoyuki; Shikama, Yayoi; Onoue, Satomi; Kimura, Junko

doi:10.1007/s00228-018-2420-x

Cited by 10 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an in vitro study, it has been demonstrated that 0.1 – 100 µM of EGCG inhibits CYP2C9 activity, and subsequently suppresses fluvastatin degradation in an EGCG-concentration dependent manner. However, a subsequent clinical study reported no significant differences in C max , AUC, and t 1/2 of fluvastatin in human subjects who were co-administered brewed green tea and GTE 36 . It is important to note that this study did not investigate the specific effect of EGCG on fluvastatin in human subjects.…”

Section: Methodsmentioning

confidence: 95%

“…It is important to note that this study did not investigate the specific effect of EGCG on fluvastatin in human subjects. Based on the findings, the research team concluded that a single administration of green tea or EGCG is unlikely to cause clinically significant interactions with fluvastatin [36].…”

Section: Epigallocatechin Gallate Increases Plasma Concentrations Of ...mentioning

confidence: 99%

See 1 more Smart Citation

An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers

et al. 2023

View full text Add to dashboard Cite

Brewed green tea, green tea extract (GTE), and its primary active compound, epigallocatechin gallate (EGCG) may interact with drugs and alter the drug’s therapeutic effectiveness ultimately leading to therapeutic failure or drug overdose. Several isolated reports have claimed that EGCG is the main active ingredient that causes these effects. Several isolated reports have claimed that EGCG is the main active ingredient that causes these effects. While a few studies aimed to uncover evidence of EGCG-drug interactions, no study has thoroughly and collectively reviewed them. EGCG is a potential cardio-protective agent used by many patients with cardiovascular diseases as a complementary medicine alongside conventional modern medications, either with or without the knowledge of their physicians. Therefore, this review focuses on the impact of concurrent EGCG supplementation on pharmacokinetics and pharmacodynamics of several commonly used cardiovascular drugs (statins, beta-blockers, and calcium channel blockers). Pubmed index was searched for keywords related to this review, without year limit and the results analysed for interactions of cardiovascular drugs with EGCG. This review concludes that EGCG increases systemic circulation of several statins (simvastatin, fluvastatin, rosuvastatin,) and calcium channel blockers (verapamil), but decreases the bioavailability of beta-blockers (nadolol, atenolol, bisoprolol). Further studies on its clinical significance in affecting drug efficacy are required.

show abstract

Section: Methodsmentioning

confidence: 95%

Section: Epigallocatechin Gallate Increases Plasma Concentrations Of ...mentioning

confidence: 99%

An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A single oral dose of 30 mg nadolol (Nadic®, Sumitomo Dainippon Pharma, Osaka, Japan) was administered in the morning of the study day with 150 mL of concomitant brewed green tea, or 1 hour after 150 mL of brewed green tea or with 150 mL of concomitant water. Brewed green tea was prepared before ingestion in every trial according to previous studies 11,12 in order to achieve an EGCG concentration of approximately 100 mg dL −1 . In brief, commercially available green tea leaves (3.0 g per 100 mL, Harada Tea Processing Co. Ltd., Shimada, Japan) were mixed with hot water (90°C) for 4 minutes with stirring 1 day before the clinical trial, and the brewed green tea was stored at 4°C until the subjects took it.…”

Section: Methodsmentioning

confidence: 99%

Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers

Misaka

Abe

Ono

et al. 2020

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

The aim of this study was to investigate the effects of a single green tea (GT), administered concomitantly or 1 hour before nadolol intake on nadolol pharmacokinetics. Methods: In a randomized 3-phase crossover study, 11 healthy volunteers received an oral administration of nadolol with, or 1 hour after preingestion of brewed GT, or with water in a volume of 150 mL. Results: Geometric mean ratio with 90% confidence interval for nadolol AUC 0-48 was 0.371 (0.303-0.439) with concomitant GT. In addition, ingestion of GT 1 hour before nadolol administration resulted in a significant reduction of nadolol AUC 0-48 with geometric mean ratio of 0.536 (0.406-0.665). There were no differences in time to maximal plasma concentration and renal clearance of nadolol among groups. Conclusion: These results suggest that single concomitant ingestion of GT substantially decreases plasma concentrations of nadolol. Moreover, the reduction in nadolol bioavailability could persist for at least 1 hour after drinking a cup of GT.

show abstract

“…As evidenced by clinical studies, the significant degree of variability in the pharmacokinetic parameters of EGCG might be explained by genetic variations in the genes encoding the drug transporters MRP2 and organic anion transporter SLC21A6 (OATP1B1). It is possible that this interindividual heterogeneity could account for the quantities of green tea polyphenols in human plasma or their potential to induce beneficial effects [ 364 ] and their potential to trigger pharmacokinetic interaction with other drugs [ 365 , 366 , 367 , 368 ].…”

Section: Egcg In Cancer Prevention and Therapy?mentioning

confidence: 99%

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Kciuk,

Alam,

Ali

et al. 2023

Molecules

View full text Add to dashboard Cite

Cellular signaling pathways involved in the maintenance of the equilibrium between cell proliferation and apoptosis have emerged as rational targets that can be exploited in the prevention and treatment of cancer. Epigallocatechin-3-gallate (EGCG) is the most abundant phenolic compound found in green tea. It has been shown to regulate multiple crucial cellular signaling pathways, including those mediated by EGFR, JAK-STAT, MAPKs, NF-κB, PI3K-AKT-mTOR, and others. Deregulation of the abovementioned pathways is involved in the pathophysiology of cancer. It has been demonstrated that EGCG may exert anti-proliferative, anti-inflammatory, and apoptosis-inducing effects or induce epigenetic changes. Furthermore, preclinical and clinical studies suggest that EGCG may be used in the treatment of numerous disorders, including cancer. This review aims to summarize the existing knowledge regarding the biological properties of EGCG, especially in the context of cancer treatment and prophylaxis.

show abstract

Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers

Abstract: Although in vitro studies indicated that EGCG and brewed green tea produce significant inhibitory effects on CYP2C9 activity, the concomitant administration of green tea and fluvastatin in healthy volunteers did not influence the pharmacokinetics of fluvastatin.

Cited by 10 publications

References 41 publications

An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers

An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers

Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Contact Info

Product

Resources

About